- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01997918
Secondary Haplo HSCT for Relapse After Initial Allogeneic HSCT
2. mai 2018 oppdatert av: University Hospital Tuebingen
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Relapse After a First Allogeneic HSCT: a Retrospective Cohort Study by the German Cooperative Transplant Study Group
Relapse of underlying hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) is frequently treated by a second allogeneic HSCT (HSCT2).
Choosing an alternative donor is often advocated to maximize chances of a graft versus tumour (GVT) effect.
We and others published that success of this strategy when using an alternative human leukocyte antigen (HLA) identical donor is limited, at least when acute leukemia is the underlying disease.
The aggressivity of the rapidly proliferating leukemia seems to prevail over GVT effects.
A more potent alloimmune response is observed following haploidentical HSCT, especially early after haploidentical HSCT.
This might be related to a fast and large expansion of natural killer (NK)-cells.
Their alloreactive effect might translate into higher rates of tumor control.
On the other hand, non-relapse complications (treatment related mortality, TRM) might be high in advanced relapsed tumour patients with heavy pretreatment and due to delayed immune reconstitution after haploidentical HSCT.
The use of a haploidentical donor for HSCT2 following a first allogeneic HSCT from an HLA identical donor has been so far only systematically evaluated in small retrospective single center reports.
Thus, in this multicenter study we aim to collect data on the extent to which participating centers employ haploidentical transplantation in the situation of relapse after HSCT2.
Studieoversikt
Status
Fullført
Detaljert beskrivelse
Relapse of underlying hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) is frequently treated by a second allogeneic HSCT (HSCT2).
Choosing an alternative donor is often advocated to maximize chances of a graft versus tumour (GVT) effect.
We and others published that success of this strategy when using an alternative HLA identical donor is limited, at least when acute leukemia is the underlying disease.
The aggressivity of the rapidly proliferating leukemia seems to prevail over GVT effects.
A more potent alloimmune response is observed following haploidentical HSCT, especially early after haploidentical HSCT.
This might be related to a fast and large expansion of NK-cells.
Their alloreactive effect might translate into higher rates of tumor control.
On the other hand, non-relapse complications (treatment related mortality, TRM) might be high in advanced relapsed tumour patients with heavy pretreatment and due to delayed immune reconstitution after haploidentical HSCT.
The use of a haploidentical donor for HSCT2 following a first allogeneic HSCT from an HLA identical donor has been so far only systematically evaluated in small retrospective single center reports.
Thus, in this multicenter study we aim to collect data on the extent to which participating centers employ haploidentical transplantation in the situation of relapse after HSCT2.
We will describe and quantify the specific patient, donor, treatment, graft and outcomes characteristics associated with the course of treatment.
To assess and control for the bias that is associated with the retrospective nature of this study, we will emphasize to collect clearly stated reasons for the decision to use a haploidentical transplant, e.g. as opposed to drug therapy or a second transplant from the original or an alternative HLA identical donor.
This is a retrospective observational cohort study.
German centers performing allogeneic HSCT are asked to contribute.
Data will be validated and missing information will be further retrieved by the four principal investigators through phone.
Final follow up will be performed in April 2014, 2014.
To be able to supply durable data on the primary endpoints, only patients receiving a haploidentical HSCT2 between 01.07.2003 and 30.06.2013 will be included.
Studietype
Observasjonsmessig
Registrering (Faktiske)
60
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Patients receiving salvage secondary haploidentical allogeneic HSCT after failure of primary allogeneic HSCT
Beskrivelse
Inclusion Criteria:
- Age >18 years at time of HSCT2
- Malignant hematologic disease
- Informed consent signed by the patients on the use of data in registry analyses
- 1st allogeneic HSCT performed from any donor, including haploidentical HSCT1
- Hematological or extramedullary relapse after HSCT1
- Haploidentical 2nd allogeneic HSCT (i.e. >= 2 Antigen mismatch family donor) between 01.07.2003 and 30.06.2013
Third or higher allogeneic HSCT does not preclude analysis as long as HSCT2 was haploidentical.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Treatment related mortality (TRM) of haploidentical HSCT2
Tidsramme: up to day 365
|
up to day 365
|
|
Toxicity of haploidentical HSCT2
Tidsramme: up to day 365
|
NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4
|
up to day 365
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
complete remission (CR) rate after haploidentical HSCT2
Tidsramme: day 100
|
day 100
|
Overall survival (OS) at 2 years after haploidentical HSCT2
Tidsramme: 2 years
|
2 years
|
Graft versus host disease (GVHD) after haploidentical HSCT2
Tidsramme: 2 years
|
2 years
|
Incidence of rejection after haploidentical HSCT2
Tidsramme: 1 year
|
1 year
|
Disease free survival (DFS) at 2 years after haploidentical HSCT2
Tidsramme: 2 years
|
2 years
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Wolfgang A Bethge, MD, University Hospital Tuebingen
- Hovedetterforsker: Christoph Schmid, MD, University Hospital Augsburg
- Hovedetterforsker: Johanna Tischer, MD, Ludwig-Maximilians University Hospital Munich
- Hovedetterforsker: Maximilian Christopeit, MD, University Hospital of Halle
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. oktober 2013
Primær fullføring (Faktiske)
30. desember 2017
Studiet fullført (Faktiske)
30. desember 2017
Datoer for studieregistrering
Først innsendt
29. oktober 2013
Først innsendt som oppfylte QC-kriteriene
27. november 2013
Først lagt ut (Anslag)
28. november 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
3. mai 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. mai 2018
Sist bekreftet
1. mai 2018
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- KTS 2. Haplo HSCT
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .